Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel Free ADMA Stock Alerts

ADMA Biologics (ADMA) Short Interest Ratio & Short Volume

ADMA Biologics logo
$8.08 +0.11 (+1.38%)
As of 11:03 AM Eastern
Compare

ADMA Biologics Short Interest Overview

As of May 15, 2026, ADMA Biologics (ADMA) had a short interest of 19.99 million shares sold short, representing 8.98% of the public float. This marks a -3.21% decrease in short interest since the prior report. The short interest ratio (days to cover) is 2.3, meaning it would take 2.3 days of the average trading volume of 5.20 million shares to cover all short positions.

Current Short Interest
19,994,416 shares
Previous Short Interest
20,658,114 shares
Change Vs. Previous Month
-3.21%
Dollar Volume Sold Short
$165.35 million
Short Interest Ratio
2.3 Days to Cover
Last Record Date
May 15, 2026
Outstanding Shares
231,773,000 shares
Short Percent of Float
8.98%
Today's Trading Volume
596,345 shares
Average Trading Volume
5,196,502 shares
Today's Volume Vs. Average
11%
Short Selling ADMA Biologics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for ADMA Biologics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

ADMA Short Interest Over Time

ADMA Days to Cover Over Time

ADMA Percentage of Float Shorted Over Time

ADMA Biologics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/15/202619,994,416 shares $165.35 million -3.2%9.0%2.26 $8.27
4/30/202620,658,114 shares $211.75 million +7.0%9.0%3.22 $10.25
4/15/202619,306,519 shares $205.61 million -12.9%8.4%3.84 $10.65
3/31/202622,175,506 shares $199.80 million -14.1%9.6%1.64 $9.01
3/13/202625,826,838 shares $391.28 million +35.0%11.3%7.12 $15.15
2/27/202619,137,458 shares $297.97 million -9.1%8.3%5.72 $15.57
2/13/202621,049,574 shares $338.69 million +8.3%9.2%11.75 $16.09
1/30/202619,439,065 shares $336.30 million +4.7%8.5%9.19 $17.30
1/15/202618,573,160 shares $325.03 million -2.1%8.1%7.22 $17.50
12/31/202518,972,317 shares $346.06 million +0.8%8.3%9.32 $18.24
12/15/202518,829,424 shares $371.50 million +1.4%8.2%7.26 $19.73
11/28/202518,563,031 shares $366.25 million -0.4%8.1%5.87 $19.73
11/14/202518,629,225 shares $289.87 million +11.9%8.1%4 $15.56
10/31/202516,649,924 shares $257.74 million -5.2%7.2%5.55 $15.48
10/15/202517,560,000 shares $264.98 million +0.9%7.6%5.2 $15.09
9/30/202517,410,000 shares $255.23 million +10.6%N/A5.4 $14.66
9/15/202515,740,000 shares $240.82 million +5.1%N/A5 $15.30
8/31/202514,980,000 shares $258.55 million +0.1%6.5%4.6 $17.26
8/15/202514,960,000 shares $254.17 million +8.9%N/A5 $16.99
7/31/202513,740,000 shares $256.94 million -5.0%6.0%4.2 $18.70
7/15/202514,470,000 shares $260.17 million -10.9%N/A4.5 $17.98
6/30/202516,240,000 shares $295.73 million +17.6%7.0%4.6 $18.21
6/15/202513,810,000 shares $287.39 million -3.5%6.0%4 $20.81
5/31/202514,310,000 shares $285.77 million +7.4%6.3%4.1 $19.97
5/15/202513,330,000 shares $255.94 million +7.9%5.9%3.7 $19.20
4/30/202512,350,000 shares $293.93 million -6.9%N/A3.6 $23.80
4/15/202513,260,000 shares $293.71 million +2.3%5.8%4.4 $22.15
3/31/202512,960,000 shares $257.13 million -14.0%5.7%4.6 $19.84
3/15/202515,070,000 shares $277.74 million +5.9%6.6%5.6 $18.43
2/28/202514,230,000 shares $233.23 million +3.6%6.3%5.8 $16.39
2/15/202513,740,000 shares $218.47 million +4.3%6.0%5.8 $15.90
1/31/202513,180,000 shares $212.86 million -2.6%N/A4.9 $16.15
1/15/202513,530,000 shares $226.09 million -0.7%N/A4.6 $16.71
12/31/202413,620,000 shares $233.58 million +11.8%N/A3.9 $17.15
12/15/202412,180,000 shares $226.43 million -5.7%N/A3.2 $18.59
11/30/202412,910,000 shares $259.62 million -9.3%N/A2.6 $20.11
11/15/202414,240,000 shares $271.13 million -6.3%N/A2.8 $19.04
10/31/202415,200,000 shares $247.91 million -5.4%N/A2.9 $16.31
10/15/202416,070,000 shares $266.44 million -5.9%N/A3.1 $16.58
9/30/202417,080,000 shares $341.43 million +37.5%N/A3.6 $19.99
The roadshow starts Monday. This stock isn't ready. (Ad)

The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the world's largest fund managers - including a section naming one small company Musk's Colossus cannot operate without. Right now, most fund managers have never heard of it. By Friday, every one of them will. Dylan Jovine has identified the name and ticker before $75 billion in new capital starts chasing the SpaceX supply chain.tc pixel

Get the stock name and ticker before the roadshow begins
9/15/202412,420,000 shares $224.68 million +30.7%N/A2.6 $18.09
8/31/20249,500,000 shares $164.45 million +5.3%N/A2.6 $17.31
8/15/20249,020,000 shares $158.66 million +3.1%N/A2.6 $17.59
7/31/20248,750,000 shares $107.45 million +5.7%N/A2.5 $12.28
7/15/20248,280,000 shares $110.87 million +13.9%N/A2.6 $13.39
6/30/20247,270,000 shares $81.28 million -23.0%N/A2.5 $11.18
6/15/20249,440,000 shares $100.35 million +2.5%N/A3.4 $10.63
5/31/20249,210,000 shares $87.96 million +9.1%N/A3.3 $9.55
5/15/20248,440,000 shares $76.80 million -3.2%N/A2.9 $9.10
4/30/20248,720,000 shares $56.85 million +7.5%N/A3.4 $6.52
4/15/20248,110,000 shares $48.50 million +11.3%N/A3.2 $5.98
3/31/20247,290,000 shares $48.11 million -8.8%N/A2.7 $6.60
3/15/20247,990,000 shares $47.86 million +18.9%N/A3 $5.99
2/29/20246,720,000 shares $36.02 million +9.3%N/A2.6 $5.36
2/15/20246,150,000 shares $33.21 million -10.1%N/A2.9 $5.40
1/31/20246,840,000 shares $35.50 million -14.8%N/A3.2 $5.19
1/15/20248,030,000 shares $40.07 million +19.0%N/A3.7 $4.99
12/31/20236,750,000 shares $30.51 million -13.6%N/A3.4 $4.52
12/15/20237,810,000 shares $32.80 million -10.2%N/A4.2 $4.20
11/30/20238,700,000 shares $32.19 million -6.3%N/A4.9 $3.70
11/15/20239,280,000 shares $35.26 million -3.1%N/A4.8 $3.80
10/31/20239,580,000 shares $32.38 million +3.9%N/A4.1 $3.38
10/15/20239,220,000 shares $29.60 million +3.3%N/A4.2 $3.21
9/30/20238,930,000 shares $31.97 million +2.8%N/A4.1 $3.58
9/15/20238,690,000 shares $32.41 million -1.9%N/A4.1 $3.73
8/31/20238,860,000 shares $34.11 million -1.7%N/A4 $3.85
8/15/20239,010,000 shares $40.91 million +8.4%N/A4.2 $4.54
7/31/20238,310,000 shares $34.49 million -2.4%N/A4.1 $4.15
7/15/20238,510,000 shares $30.38 million +2.7%N/A4.2 $3.57
6/30/20238,290,000 shares $30.59 million -19.8%N/A3.9 $3.69
6/15/202310,340,000 shares $41.26 million -1.2%N/A4.6 $3.99
5/31/202310,460,000 shares $42.57 million -6.4%N/A4.4 $4.07
5/15/202311,170,000 shares $46.80 million -1.2%N/A4.6 $4.19
4/30/202311,310,000 shares $37.89 million -2.8%N/A5.1 $3.35
4/15/202311,640,000 shares $37.02 million -6.8%N/A4.9 $3.18
3/31/202312,490,000 shares $41.34 million +14.4%N/A5.1 $3.31
3/15/202310,920,000 shares $34.18 million +0.8%N/A4.4 $3.13
2/28/202310,830,000 shares $38.45 million -6.2%N/A3.8 $3.55
2/15/202311,550,000 shares $41.35 million -9.7%N/A3.9 $3.58
1/31/202312,790,000 shares $47.20 million +6.1%N/A3.8 $3.69
1/15/202312,050,000 shares $40.97 million -5.3%N/A3.7 $3.40
12/30/202212,720,000 shares $49.35 million +1.8%N/A4 $3.88
12/15/202212,500,000 shares $44.50 million -37.4%N/A3.7 $3.56
11/30/202219,980,000 shares $66.73 million -8.1%N/A6 $3.34
11/15/202221,740,000 shares $70.44 million -15.9%N/A7.2 $3.24
10/31/202225,860,000 shares $72.93 million +0.2%N/A9.1 $2.82
10/15/202225,820,000 shares $67.65 million -6.3%N/A9.5 $2.62
9/30/202227,560,000 shares $66.97 million +6.0%N/A10.4 $2.43
9/15/202225,990,000 shares $70.43 million -2.0%N/A9 $2.71
8/31/202226,520,000 shares $71.60 million -6.2%N/A9.8 $2.70
SpaceX is offering you shares. Don't take them. (Ad)

SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. But at a $1.75 trillion valuation and 266 times earnings, early institutional holders may be looking for someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure behind Colossus - still trading at a fraction of its potential value. No IPO allocation required.tc pixel

Get the backdoor ticker free before the SpaceX IPO launches
8/15/202228,270,000 shares $68.13 million -1.7%N/A10.7 $2.41
7/31/202228,760,000 shares $61.55 million +0.1%N/A11.1 $2.14
7/15/202228,730,000 shares $66.08 million +1.3%N/A10.2 $2.30
6/30/202228,360,000 shares $56.15 million +11.0%N/A9.8 $1.98
6/15/202225,540,000 shares $51.85 million +1.0%N/A8.1 $2.03
5/31/202225,300,000 shares $51.87 million +5.4%N/A9.3 $2.05
5/15/202224,010,000 shares $42.26 million +4.5%N/A9.2 $1.76
4/30/202222,980,000 shares $42.28 million +3.1%N/A9.1 $1.84
4/15/202222,300,000 shares $44.82 million +10.1%N/A9.3 $2.01
3/31/202220,250,000 shares $37.06 million +25.0%N/A8.8 $1.83
3/15/202216,200,000 shares $25.11 million +10.7%N/A8.2 $1.55
2/28/202214,640,000 shares $23.57 million +4.4%N/A7.4 $1.61
2/15/202214,020,000 shares $23.41 million +36.0%N/A7.2 $1.67
1/31/202210,310,000 shares $14.95 million +1.2%N/A4.6 $1.45
1/15/202210,190,000 shares $14.27 million -4.1%N/A4.5 $1.40
12/31/202110,620,000 shares $14.97 million +6.6%N/A4.1 $1.41
12/15/20219,960,000 shares $12.75 million -1.2%N/A4 $1.28
11/30/202110,080,000 shares $13.91 million -9.7%N/A4.1 $1.38
11/15/202111,160,000 shares $17.30 million -7.4%N/A3.5 $1.55
10/29/202112,050,000 shares $15.54 million +4.4%N/A3.5 $1.29
10/15/202111,540,000 shares $12.69 million +10.5%N/A3.5 $1.10
9/30/202110,440,000 shares $11.80 million -9.9%8.3%3.6 $1.13
9/15/202111,590,000 shares $13.91 million -5.2%9.2%3.7 $1.20
8/31/202112,220,000 shares $16.37 million -3.3%9.7%3.9 $1.34
8/13/202112,640,000 shares $18.83 million -5.1%10.0%4.9 $1.49
7/30/202113,320,000 shares $20.65 million +14.2%10.6%6.3 $1.55
7/15/202111,660,000 shares $17.26 million +14.8%9.2%1.8 $1.48
6/30/202110,160,000 shares $16.26 million -16.9%8.1%1.5 $1.60
6/15/202112,220,000 shares $21.75 million +11.4%9.7%1.8 $1.78

ADMA Short Interest - Frequently Asked Questions

Short interest is the volume of ADMA Biologics shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 19,994,416 shares of ADMA short. 8.98% of ADMA Biologics' shares are currently sold short. Learn More on ADMA Biologics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ADMA shares currently have a short interest ratio of 2.3. Learn More on ADMA Biologics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.98% of ADMA Biologics' floating shares are currently sold short.

ADMA Biologics saw a drop in short interest in May. As of May 15th, there was short interest totaling 19,994,416 shares, a drop of 3.2% from the previous total of 20,658,114 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

8.98% of ADMA Biologics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to ADMA Biologics: ACADIA Pharmaceuticals Inc. (9.04%), Allogene Therapeutics, Inc. (14.11%), Immunovant, Inc. (10.10%), Kymera Therapeutics, Inc. (14.48%), Lantheus Holdings, Inc. (10.06%), Protagonist Therapeutics, Inc. (11.96%), Spyre Therapeutics, Inc. (16.96%), Mirum Pharmaceuticals, Inc. (15.70%), PTC Therapeutics, Inc. (13.06%), Rhythm Pharmaceuticals, Inc. (12.84%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($80.71 billion), Invesco QQQ ($47.96 billion), iShares Russell 2000 ETF ($22.13 billion), Western Digital Corporation ($14.35 billion), Sandisk Corporation ($12.86 billion), Salesforce Inc. ($10.89 billion), Nebius Group N.V. ($9.92 billion), SPDR S&P Biotech ETF ($9.72 billion), Lumentum Holdings Inc. ($8.89 billion), and iShares 20+ Year Treasury Bond ETF ($8.18 billion). View all of the most shorted stocks.

Short selling ADMA is an investing strategy that aims to generate trading profit from ADMA Biologics as its price is falling. ADMA shares are trading up $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for ADMA Biologics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ADMA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ADMA, twice per month. The most recent reporting period available is May, 15 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like ADMA:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:ADMA) was last updated on 6/8/2026 by MarketBeat.com Staff.
From Our Partners
America's AI Future Needs a Domestic Fuel Chain
AI dominance requires power at a scale most investors have not priced in - and nuclear energy is emerging as a...
i2i Marketing Group, LLC | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Not much time left. See why this Former CIA Economistsays investors may be missing this opportunity:
Institutions hear first. Insiders position early. By the time ordinary investors get access, the best part of ...
The Oxford Club | Sponsoredtc pixel
BNZI Breakout Watch: AI Growth Meets Turnaround Setup!
Banzai International (NASDAQ: BNZI) posted full-year 2025 revenue of $12.2 million, up 169% year-over-year, wi...
Huge Alerts | Sponsoredtc pixel
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...
Porter & Company | Sponsoredtc pixel
The "hidden" half of the SpaceX IPO
Most investors are focused on the SpaceX IPO - but the bigger opportunity may lie elsewhere. On Feb. 2, Elon M...
Weiss Ratings | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel